[1] Waldman E A, Luhm K R, Monteiro S A, et al. Surveillance of adverse effects following vaccination and safety of immunization programs[J].Rev Saude Publica,2011, 45(1):173-184. [2] European Medicines Agency. Guidelineon goodpharmacovigilancepractices:Module VIII- Post-authorisation safety studies[EB/OL].(2013-04-19) [2016-09-01].http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000377.jsp&mid=WC0b01ac058066e979. [3] Bonhoeffer J, Black S, Izurieta H, et al. Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe[J].Biologicals, 2012, 40(5):393-397. [4] World Health Organization. Global manual on surveillance of adverse events following immunization.[EB/OL].(2014-09) [2016-09-01].http://www.who.int/vaccine_safety/publications/en/. [5] World Health Organization. Global vaccine safety blueprint[EB/OL].(2012-02) [2016-09-01]. http://www.who.int/vaccine_safety/en/. [6] Stang P E, Ryan P B, Racoosin J A,et al. Advancing thescienceforactive surveillance: rationale and design for the Observational Medical Outcomes Partnership[J]. Annals of Internal Medcine, 2010, 2,153(9):600-606. [7] 陈哲,李斌,史录文,等.美国FDA迷你哨点中公共数据库模型的介绍及对我国的启示[J].药事管理, 2013, 24(41):3844-3846. [8] 武文娣,刘大卫.疫苗上市后安全性主动监测及其流行病学研究方法[J].中国疫苗和免疫, 2016, 22(2):221-229. [9] 周晓枫,刘青,蔡兵,等. 全球上市后药品主动监测系统概况[J].药物流行病学杂志, 2012, 21(7):338-342. [10] Huang Y L, Moon J, Segal J B. A comparison of active adverse event surveillance systems worldwide[J]. Drug Saf, 2014, 37(8):581-596. [11] Liu D, Wu W, Li K,et al. Surveillance of adverse events following immunization in China: Past, present, and future[J].Vaccine,2015, 33(32):4041-4046. [12] 叶家楷,李克莉,许涤沙,等.中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J].中国疫苗和免疫,2016,22(2):125-137. [13] 卫生部办公厅,国家食品药品监督管理局办公室.全国疑似预防接种异常反应监测方案[EB/OL].(2010-06-03)[2016-09-01].http://114.255.93.201/ztzl/ymaqxjc/xgwj/201307/t20130726_5551.html. [14] 王亚丽,董铎,王丹,等. 美国疫苗上市后安全性监测给我们的启示[J].中国药事, 2015, 29(9):19-22. [15] 武文娣,刘大卫. 疫苗上市后安全性主动监测及其流行病学研究方法[J].中国疫苗和免疫, 2016, 22(2): 221-227. |